171 related articles for article (PubMed ID: 36224534)
1. Targeting UBR5 in hepatocellular carcinoma cells and precise treatment via echinacoside nanodelivery.
Wang M; Ma X; Wang G; Song Y; Zhang M; Mai Z; Zhou B; Ye Y; Xia W
Cell Mol Biol Lett; 2022 Oct; 27(1):92. PubMed ID: 36224534
[TBL] [Abstract][Full Text] [Related]
2. Anticancer effects of echinacoside in hepatocellular carcinoma mouse model and HepG2 cells.
Ye Y; Song Y; Zhuang J; Wang G; Ni J; Xia W
J Cell Physiol; 2019 Feb; 234(2):1880-1888. PubMed ID: 30067868
[TBL] [Abstract][Full Text] [Related]
3. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
Zhao R; Li T; Zheng G; Jiang K; Fan L; Shao J
Biomaterials; 2017 Oct; 143():1-16. PubMed ID: 28755539
[TBL] [Abstract][Full Text] [Related]
5. [Research progress on pharmacological activities of echinacoside].
He W; Fang T; Tu P
Zhongguo Zhong Yao Za Zhi; 2009 Feb; 34(4):476-9. PubMed ID: 19459316
[TBL] [Abstract][Full Text] [Related]
6.
Yuan P; Fu C; Yang Y; Adila A; Zhou F; Wei X; Wang W; Lv J; Li Y; Xia L; Li J
Integr Cancer Ther; 2021; 20():15347354211013085. PubMed ID: 33949239
[No Abstract] [Full Text] [Related]
7. pH-Sensitive mesoporous silica nanoparticles anticancer prodrugs for sustained release of ursolic acid and the enhanced anti-cancer efficacy for hepatocellular carcinoma cancer.
Li T; Chen X; Liu Y; Fan L; Lin L; Xu Y; Chen S; Shao J
Eur J Pharm Sci; 2017 Jan; 96():456-463. PubMed ID: 27771513
[TBL] [Abstract][Full Text] [Related]
8. Echinacoside suppresses pancreatic adenocarcinoma cell growth by inducing apoptosis via the mitogen-activated protein kinase pathway.
Wang W; Luo J; Liang Y; Li X
Mol Med Rep; 2016 Mar; 13(3):2613-8. PubMed ID: 26846399
[TBL] [Abstract][Full Text] [Related]
9. E3 ubiquitin ligase UBR5 promotes pancreatic cancer growth and aerobic glycolysis by downregulating FBP1 via destabilization of C/EBPα.
Chen L; Yuan R; Wen C; Liu T; Feng Q; Deng X; Du Y; Peng X
Oncogene; 2021 Jan; 40(2):262-276. PubMed ID: 33122826
[TBL] [Abstract][Full Text] [Related]
10. Secalonic Acid-F, a Novel Mycotoxin, Represses the Progression of Hepatocellular Carcinoma via MARCH1 Regulation of the PI3K/AKT/β-catenin Signaling Pathway.
Xie L; Li M; Liu D; Wang X; Wang P; Dai H; Yang W; Liu W; Hu X; Zhao M
Molecules; 2019 Jan; 24(3):. PubMed ID: 30678274
[TBL] [Abstract][Full Text] [Related]
11. GSTZ1 deficiency promotes hepatocellular carcinoma proliferation via activation of the KEAP1/NRF2 pathway.
Li J; Wang Q; Yang Y; Lei C; Yang F; Liang L; Chen C; Xia J; Wang K; Tang N
J Exp Clin Cancer Res; 2019 Oct; 38(1):438. PubMed ID: 31666108
[TBL] [Abstract][Full Text] [Related]
12. UBR5 regulates proliferation and radiosensitivity in human laryngeal carcinoma via the p38/MAPK signaling pathway.
Wang K; Tang J; Liu X; Wang Y; Chen W; Zheng R
Oncol Rep; 2020 Aug; 44(2):685-697. PubMed ID: 32468011
[TBL] [Abstract][Full Text] [Related]
13. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
Xue H; Yu Z; Liu Y; Yuan W; Yang T; You J; He X; Lee RJ; Li L; Xu C
Int J Nanomedicine; 2017; 12():5271-5287. PubMed ID: 28769563
[TBL] [Abstract][Full Text] [Related]
14. Antiosteoporotic activity of echinacoside in ovariectomized rats.
Li F; Yang X; Yang Y; Guo C; Zhang C; Yang Z; Li P
Phytomedicine; 2013 Apr; 20(6):549-57. PubMed ID: 23428402
[TBL] [Abstract][Full Text] [Related]
15. Modulation of myocardin function by the ubiquitin E3 ligase UBR5.
Hu G; Wang X; Saunders DN; Henderson M; Russell AJ; Herring BP; Zhou J
J Biol Chem; 2010 Apr; 285(16):11800-9. PubMed ID: 20167605
[TBL] [Abstract][Full Text] [Related]
16. UBR-box containing protein, UBR5, is over-expressed in human lung adenocarcinoma and is a potential therapeutic target.
Saurabh K; Shah PP; Doll MA; Siskind LJ; Beverly LJ
BMC Cancer; 2020 Aug; 20(1):824. PubMed ID: 32867711
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral Administration of Thermosensitive Hydrogel Co-Loaded with Norcantharidin Nanoparticles and Doxorubicin for the Treatment of Hepatocellular Carcinoma.
Gao B; Luo J; Liu Y; Su S; Fu S; Yang X; Li B
Int J Nanomedicine; 2021; 16():4073-4085. PubMed ID: 34163160
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of miR-299-5p inhibits the progression of hepatocellular carcinoma by targeting SIAH1.
Jiang X; Shen X
Bull Cancer; 2018 Oct; 105(10):873-883. PubMed ID: 30266288
[TBL] [Abstract][Full Text] [Related]
19. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
20. UBR5 is a novel E3 ubiquitin ligase involved in skeletal muscle hypertrophy and recovery from atrophy.
Seaborne RA; Hughes DC; Turner DC; Owens DJ; Baehr LM; Gorski P; Semenova EA; Borisov OV; Larin AK; Popov DV; Generozov EV; Sutherland H; Ahmetov II; Jarvis JC; Bodine SC; Sharples AP
J Physiol; 2019 Jul; 597(14):3727-3749. PubMed ID: 31093990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
